Cannabis shenanigans: advocating for the restoration of an effective treatment of pain following spinal cord injury

Canna Clinical TrialsLeave a comment

Cannabis is an effective treatment for pain following spinal cord injury that should be available to patients and researchers. The major argument against the rescheduling of cannabis is that the published research is not convincing. This argument is disingenuous at best, given that the evidence has been presented and rejected at many points during the political dialog. People living with chronic pain should not have to risk addiction, social stigma, restrictions on employment and even criminal prosecution in order to deal with their pain. It is time to end the shenanigans and have an open, transparent discussion of the true benefits of this much-beleaguered medicine.

Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation

Canna Clinical TrialsLeave a comment

There is considerable public and political interest in the use of cannabis products for medical purposes. The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care.

Structural barriers in access to medical marijuana in the USA-a systematic review protocol

Canna Clinical TrialsLeave a comment

There are 43 state medical marijuana programs in the USA, yet limited evidence is available on the demographic characteristics of the patient population accessing these programs. Moreover, insights into the social and structural barriers that inform patients’ success in accessing medical marijuana are limited. A current gap in the scientific literature exists regarding generalisable data on the social, cultural, and structural mechanisms that hinder access to medical marijuana among qualifying patients.